Answers are grounded in this paper and cite their sources.
Validation demonstrates improved risk stratification for ovarian cancer, indicating that polygenic risk scores may enhance targeted prevention efforts.
Ovarian cancer is the leading cause of death among gynecological cancers due to its late diagnosis, but risk stratification for targeted prevention can improve outcomes. To identify women at risk of ovarian cancer, pathogenic variant testing is used, especially for those with a family history of the disease. However, high-risk genetic variants are rare, accounting for < 20% of ovarian cancer cases overall. More recently, clinical models that help identify ovarian cancer cases incorporate polygenic risk for improved risk stratification. Herein, we cross-validate a polygenic risk integrated clinical model called the refined risk model, in a nested case-control population from the Nurses’ Health Study. The refined risk model is compared with a clinical risk score and polygenic risk score model respectively. The odds ratios per standard deviation were 1.26 (1.01, 1.48), 1.13 (0.96, 1.33) and 1.22 (1.04, 1.43) with corresponding AUCs of 0.56 (0.51, 0.61), 0.54 (0.49, 0.59), 0.55 (0.50, 0.60) for the refined risk, clinical risk, and polygenic risk models, respectively. Population screening has been assessed over the years, and while stage shifting in the screened population has occurred, the mortality benefit was not evident. However, as treatments for ovarian cancer improve, the benefits of a risk-stratified approach to screening are expected to grow.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: